). Several recent reports have shown s o w patients with GlaoZlaao's thrombasthenia (GT) to have a defect in platelet membrane glycoproteins. We have followed three siblings in a Guamanian family with severe qualitative platelet disorder clinicallv diagnosed as OT. All three have manifested spontaneous bruising and muroua
membrane bleeding since birth. Major bleeding associated with minimal trauma has required repeated platelet aod blood transfusions. The lab data have been identical io these three patieots on repeated testing In two separate laboratories. All three have shown prolonged bleeding times, normal platelet counts and platelet morphology. no clot retraction, no aggregation to epinephrine. ADP, or thrombin and normal aggregation to ristocetin. Slight aggregation was seen with full strength collagen.
atelet membrane proteins from our patients were labeled withl"I using the lactoperoxidase technique. Solubilized labeled and unlabeled membrane proteins were subjected to polyaurylamide gel electrophoresis and evaluated by protein and glycoproteio staining as well as determining the sequential radioactivity of 1 mm gel slices. Normal staining and radioactive patterns were noted in every instance. We conclude that patients with the clinical and laboratory profile of GT reflects a full spectrum of variable molecular abnormalities, since we could not demonstrate abnonnal membrane proteins. The pathogenesis of childhood ITP is not well understood. To explore the role of the humoral immune system in ITP, bone marrow (BM) and splenic (Sp) lymphocytes from ITP and control children were cultured and in vitro IgG production was measured; in some cases latelet speZficTE was assessed. Platelet-associated IgG (PAI~GP was also determined as a meaaure of platelet-bound antibody or complexes. BM and Sp cells were cultured in 20% fetal calf serum, Dulbecco's medium, for 10 days. The Fab-anti-Fab immunoassay was used in all IgG determinations. Platelet specificity was determined using an IgG absorption technique. PAIgG of circulating platelets from control and ITP subjects was assayed directly after washing the platelets by gel filtration. Mean BM s nthesis rates (ngI ~110' l$qhocytes/day) of acute and chronic I& cases were 219+9$ and 61 + 16; both were significantly greater than control vaTues of 9 8 6 2 (p<0.01 and 0.001 respectively The purpose of this study was to develop a quantitative method for factor I1 antigen in human plasma utilizing the sensitivity and precision of RIA. Factor I1 was isolated by chromato technique and shared a single band on electrophoresis. I ?54phic tagged factor I1 was prepared by a standard chloramine-T oxidation and sodium metabisulfite reduction. Antigen levels were then determined by classical double antibody radioimmunoassay. A dose response curve was generated by adding known amounts of normal human plasma to human barium sulfate-absorbed oxalated plasma. A straight line relationship existed between 15 to 140% coagulant activity (CA) and 7 to 50 vglml antigen content. Plasma factor I1 antigen in 20 normals was 29.63 f 4.6 vglml (mean t S.D.).
Eight patients with induced vitamin K deficiency revealed normal antigen levels (30.13) and reduced CA (20) whereas three patients with severe hepatocellular disease were found to have reduced antigen and CA levels (6.7 vglml and 40% activity). The use of the RIA for measuring prothrombin protein in conjunction with coagulation factor assays could have clinical application in studying the mechanism of action of vitamin K, the developmental aspects of factor I1 production and activation, and in understanding acquired coagulopathies. In vitro semisolid agar culture has been used to characterize and predict relapse in myeloid leukemias. We evaluated 5 children with ALL on the same drug regimen wlth sequential BM and CFC on day 0, 14, 28, and 83 or 138 to characterize the CFC in ALL and compare cytologic methods to CFC to predict chemotherapeutic effect and relapse. Feeder underlayers were prepared from 1x106 normal human WBC in 0.3% agar and McCoys media as a source ofCSF; 2x105 nucleated marrow cells were overlayered. Colonies were counted at day 14 and compared to the peripheral blood absolute neutrophil count (ANC) and Giemsa stained BM. BM cellularity was ranked from 0-4 (3-normoelar) .
SERIAL ASSESSMENT OF BONE MARROW (BM) COLONY FORMING

CAPACITY (CFC) IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL
DAY Mean ANC % Blasts Av. Cellularity CFU-C+SEM/2xlO' cells 0 500 60% 1.0 1.33f0.32-9.3TO.32 1% 3.0 5.OCO-56.e6.0 831138 2000 There was poor correlation between CFU-C and ANC. However. an increase in CFU-C was noted with impending remission induction as the BM was reconstituted with myeloid precursors. This was most consistently noted when serial determinatioos were performed on an individual. In one patient no increase in CFU-C was noted despite cytologic evidence of remission; this patient subsequently relapsed. Serial assessment of CFU-C may be helpful in predicting relapse before morphological evidence on routine BM preparations, but does not help in predicting chemotherapeutically induced neutropenia.
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BONE MARROW CULTURES IN CHILDREN WITH FANCONI'S ANE-
23 MIA AND T.A.R. SYNDROME. Victor Lui. Abdelsalaml. Prevention of iron deficiency in low birth weight infants requires iron supplementation before the age when neonatal iron stores are exhausted. In order to determine this age, we measured hemoglobin (Hb), mean corpuscular volune(MCV), serum iron/iron binding capacity ( 9 Sat), serum ferritin (SF), and reticulocyte count (retic) at 0.5, 1, 2, 3, 4 and 5 or 6 mo of age in 117 infants whose birth weights were between 1000 and ZOO0 g. All received banked breast milk in the hospital and breast milk or cows' milk formula later. A daily vitamin supplement included 5 IU vitamin E as tocopherol polyethylene glycol-1000 sucrinate. Infants with odd birth dates received 2 mg iron as ferrous sulfate/krj/d starting at0.5 m;thos& with even birth dates received no additional iron unless they developed anemia (Hb<7 g/dl at 2 mo, <9 at 3 mo, <9.5 at 4 mo, and <10.4 at 5 mo). At 2 mo, only the SF was significantly lower in the no-iron group (p<0.021; Hb and retic showed no evidence of vitamin E deficiency. At 3 mo, Hb, MCV, 9 Sat and SF were all lower (p<0.001, <0.01, c0.001 and <0.02) in the no-iron group. There was no significant difference between infants who were changed to formula and those who were still exclusively breast fed. The results indicate that low birth weight infants who receive no supplemental iron may develop iron deficiency by 3 mo of age. An iron dose of 2 mg/kq/d started at 2 weeks of age is adequate to prevent iron deficiency.
